Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Contacts: Andrea Hofelich, NPC, 202-827-2078, ahofelich@npcnow.org
Cary Conway, IBI, 972-731-9242, cary@conwaycommunication.com 
Mary Masson, V-BID Center, 734-764-2220, mfmasson@med.umich.edu

New Report Urges Employers, Researchers and Policy Makers to Rethink How They Measure Health Care Results

University of Michigan and Integrated Benefits Institute research indicates need to look beyond medical claims to accurately measure health investments

San Francisco, CA & Washington, DC (February 28, 2011) -- Understanding the full value of improved health, including improvements in workforce productivity, lost time and medical costs, is essential in helping employers seek the best value for their health investments, according to a new study released today. The study authors note that defining value for employers in this way could substantially transform the provision of health care benefits in the U.S. health care system.

The study, Synergies at Work: Realizing the Full Value of Health Investments, stresses what employers need in health care decision making, provides a framework for evaluating health-related investments, and supplements the analysis with case studies featuring eight employers. The paper was written by A. Mark Fendrick, MD, co-director of the University of Michigan Center for Value-Based Insurance Design (V-BID Center), and Thomas Parry, PhD, president, and Kimberly Jinnett, PhD, research director, both of the Integrated Benefits Institute (IBI). The National Pharmaceutical Council (NPC) funded and published the paper.

“Employers can contribute greatly to the transformation of the health system by focusing on value and not simply on financing and who pays,” said Dr. Fendrick. “It is imperative that we move beyond the current paradigm of exclusively measuring medical offsets, and include measurement of the effects in increased productivity that accompanies improvements in health.”

For employers, and to a great extent the broader health care consumer population, impacts of health investments are traditionally measured in terms of medical costs and savings alone. This approach ignores value and potential return on investment from health-related productivity increases (including reductions in health-related work absence and disability and improved job performance) and enhanced quality of life for employees and their families. For employers, recognition of the additional human capital value of their health investments would help support initiatives to improve employee health and productivity.

With the more limited, traditional approach, employers generally undervalue the impact of improved health outcomes to businesses and their employees. According to IBI’s research-based modeling tool, the Full Cost Estimator, for a 10,000-life sample employer in the health care services sector, medical care costs amount to less than 30% of all health-related costs for workers. The remainder stems from wage-replacement payments and lost productivity from absence or reduced job performance from ill health. At the same time, IBI surveys of chief financial officers demonstrate potential acceptance for considering the human capital impacts of workforce health, but most employers have not developed actionable data on these non-medical costs.

“Including a measure of the economic benefits of good health that reflects the true costs of ill health and the full savings from health improvement would immediately allow decision-makers and payers to make better choices as to how much to invest in health care, prevention and wellness, as well as how to determine the specific services in which to invest,” said Dr. Parry.

The study notes that employers face challenges in gathering the right information needed to make decisions. To fully assess the impact of ill health and health-related interventions, employers need to incorporate evidence beyond medical claim data, such as intervention results, incidence and duration of workplace absence and disability, and validated self-report surveys, among other data.

“In today’s health care and economic environment, it is now more important than ever to fully understand the impact of health care decisions on workforce productivity,” said NPC President Dan Leonard. “This framework for evaluating health investments provides a useful tool to help employers and others invest wisely in health.”

Synergies at Work was released today at the IBI/NBCH Health and Productivity Forum. Electronic copies are available online; print copies can be ordered from NPC at info@npcnow.org.

About the University of Michigan Center for Value-Based Insurance Design

The University of Michigan Center for Value-Based Insurance Design (V-BID Center) is the leading advocate for development, implementation and evaluation of innovative health benefit plans. Since 2005, the Center has been actively engaged in understanding the impact of value-based insurance design and collaborating with employers, health plans, policy leaders, and academics, to improve clinical outcomes and enhance economic efficiency of the U.S. health care system. For more V-BID information and resources, please visit: www.vbidcenter.org.

About the Integrated Benefits Institute

The Integrated Benefits Institute (IBI) provides employers and their supplier partners with resources for demonstrating the business value of health. As a pioneer, leader and nonprofit supplier of health and productivity research, measurement and benchmarking, IBI is the trusted source for benefits performance analysis, research-based approaches, and forums for information and education. IBI’s programs, resources and expert member networks advance understanding about the link between–and the impact of–health-related productivity on corporate America’s bottom line. More information is available at www.ibiweb.org.

About the National Pharmaceutical Council

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org.

# # #

Newsletter Volume

E.V.I.dently October 2014

Message From NPCMind the Gap: Improving Quality Measurement in Accountable Care SystemsOur society is obsessed with quality, from the cars that we...
Blog Post

Assessing the Value of Drugs for Formulary Decisions

Some of the National Pharmaceutical Council's (NPC) research partners participated today on a panel, "Best Practices for Assessing the Value of Drugs...
Newsletter Volume

E.V.I.dently September 2014

Message From NPCPatient Access to Medicines: A Growing ChallengeFor health care consumers, the rationale for why some medicines are covered by their...
YouTube Videos

Access to Specialty Medications & Value-Based Insurance Design

Specialty medications have been making health care headlines because of their effectiveness and higher costs. How can we ensure that patients will...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer

WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...
Press Release

Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Council’s Chairman of the Board

WASHINGTON, DC (November 2, 2012)–The National Pharmaceutical Council (NPC) today announced that John Gargiulo, President & CEO, Daiichi Sankyo,...
Press Release

Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity

(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
Commentary and Testimony Page

High Stakes for Setting Research Standards

What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...
Commentary and Testimony Page

Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making

The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
Commentary and Testimony Page

Comparative Effectiveness Research and the Changing Health Care Landscape

This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...
YouTube Videos

Access to Specialty Medications & Value-Based Insurance Design

Specialty medications have been making health care headlines because of their effectiveness and higher costs. How can we ensure that patients will...
YouTube Videos

Engaging Consumers in Today's Changing Health Care Payment and Delivery Environment

The current health care delivery system is evolving from a fee-for-service system to one that is performance-based. How does this shift impact...
YouTube Videos

Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design

Access to specialty medications is a particularly pressing issue for many people who rely on these treatments for conditions that are often very...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
Blog Post

Assessing the Value of Drugs for Formulary Decisions

Some of the National Pharmaceutical Council's (NPC) research partners participated today on a panel, "Best Practices for Assessing the Value of Drugs...
Blog Post

PCORI Grants, HEOR & FDA Guidance Top CER Tweets of the Week (July 21-25)

What were some of the popular comparative effectiveness research (CER)-related topics on Twitter this week? We saw keen interest in the Patient-...
Blog Post

#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

#TBT: V-BID: Getting More Health Out Of Every Health Care Dollar

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

Research

  •  
  • 1 of 40
  • >

Commentary & Testimony